IVIG-associated anterior uveitis resolving after switch to subcutaneous immunoglobulin.

INTRODUCTION

Intravenous immunoglobulin (IVIG) therapy can occasionally induce unexpected inflammatory complications.

MATERIALS AND

METHODS

A case report and literature review.

RESULTS

We report a patient with hypogammaglobulinemia and systemic autoimmunity who developed reproducible unilateral anterior uveitis following IVIG administration across multiple formulations. Discontinuation of IVIG resolved the ocular inflammation but caused underlying disease exacerbation. Transition to facilitated subcutaneous immunoglobulin (SCIG) achieved stable serum IgG levels and maintained complete ocular and systemic remission over a four-year follow-up period.

CONCLUSION

This case demonstrates peak-driven immune activation as a plausible mechanism for IVIG-induced uveitis and highlights SCIG as a safe, effective therapeutic alternative that bypasses rapid peak IgG dynamics while preserving immune protection.